Linked Data API

Show Search Form

Search Results

1668183
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Accident and Emergency Departments: Sotrovimab more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many and what proportion of hospitals with accident and emergency units have supplies of Sotrovimab. more like this
star this property tabling member constituency St Albans more like this
star this property tabling member printed
Daisy Cooper more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 500 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-13more like thismore than 2023-11-13
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.</p><p>The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.</p><p>Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.</p> more like this
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property grouped question UIN 501 more like this
star this property question first answered
less than 2023-11-13T10:39:40.997Zmore like thismore than 2023-11-13T10:39:40.997Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4769
star this property label Biography information for Daisy Cooper more like this
1668185
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Sotrovimab more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of anti-viral drug Sotrovimab for immunocompromised patients. more like this
star this property tabling member constituency St Albans more like this
star this property tabling member printed
Daisy Cooper more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 501 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-13more like thismore than 2023-11-13
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.</p><p>The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.</p><p>Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.</p> more like this
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property grouped question UIN 500 more like this
star this property question first answered
less than 2023-11-13T10:39:41.043Zmore like thismore than 2023-11-13T10:39:41.043Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4769
star this property label Biography information for Daisy Cooper more like this
1668298
star this property registered interest false more like this
star this property date less than 2023-11-08more like thismore than 2023-11-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cystic Fibrosis: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will take steps to ensure the continued NHS funding of modulator therapies that are used to treat (a) children, (b) new patients and (c) other patients with cystic fibrosis. more like this
star this property tabling member constituency East Londonderry more like this
star this property tabling member printed
Mr Gregory Campbell more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 710 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-13more like thismore than 2023-11-13
star this property answer text <p>Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.</p><p>NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.</p> more like this
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-13T10:43:17.563Zmore like thismore than 2023-11-13T10:43:17.563Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
1409
star this property label Biography information for Mr Gregory Campbell more like this
1668572
star this property registered interest false more like this
star this property date less than 2023-11-08more like thismore than 2023-11-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Prescription Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure adequate levels of supply of medication prescribed for (a) epilepsy, (b) hormone replacement therapy and (c) ADHD. more like this
star this property tabling member constituency Bedford more like this
star this property tabling member printed
Mohammad Yasin more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 882 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-13more like thismore than 2023-11-13
star this property answer text <p>The Department has well-established procedures to deal with medicine shortages and works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.</p><p>We are aware of a current supply issue with generic lamotrigine 5mg dispersible tablets for epilepsy. We have issued comprehensive management guidance to the National Health Service highlighting the availability of alternative products.</p><p>There have been issues with the supply of a limited number of hormone replacement therapy (HRT) products, primarily due to very sharp increases in demand, but the supply position for many of those products has improved considerably over the last year. Only one of the 23 Serious Shortage Protocols issued since April 2022 remains in place. We continue to engage with suppliers individually to address these issues and improve resilience in the short, medium and long term. We are also holding quarterly roundtables with manufacturers, wholesalers and community pharmacists to monitor progress and agree what more needs to be done to ensure supply is sufficient to meet demand. The eighth HRT supply roundtable is expected to be held in January 2024.</p><p>We are aware of disruptions to the global supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD). Some issues are now resolving. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. We are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p>
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-13T10:45:48.13Zmore like thismore than 2023-11-13T10:45:48.13Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4598
star this property label Biography information for Mohammad Yasin more like this
1667521
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Antibiotics more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether he plans to take steps to make (a) Cefiderocol and (b) Ceftazidimethose available on the NHS. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 220 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-09more like thismore than 2023-11-09
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE published guidance in August 2022 recommending both ceftazidime with avibactam and cefiderocol for treating severe drug-resistant gram-negative bacterial infections. This was as part of a project to test a new health technology evaluation process and payment model for antimicrobial products. NHS England has now issued contracts with the suppliers and cefiderocol and ceftazidime with avibactamare available for clinicians to prescribe in line with NICE’s recommendations.</p> more like this
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-09T17:51:11.817Zmore like thismore than 2023-11-09T17:51:11.817Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1667523
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Osteoporosis: Romosozumab more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether his Department has a planned timescale for when romosozumab will be available in the NHS for the treatment of Osteoporosis. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 222 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-09more like thismore than 2023-11-09
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.</p><p>NICE published guidance in May 2022 recommending romosozumab for treating severe osteoporosis in people after menopause who are at high risk of fracture. Romosozumab is therefore available for clinicians to prescribe to NHS patients who meet the specified criteria, in line with NICE’s recommendations.</p> more like this
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-09T10:25:40.367Zmore like thismore than 2023-11-09T10:25:40.367Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1667530
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Health: Working Hours more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of night work on (a) the level of risk of diagnosis with diabetes, (b) the level of risk of diagnosis with cardiovascular disease and (c) other health outcomes. more like this
star this property tabling member constituency Coventry North West more like this
star this property tabling member printed
Taiwo Owatemi more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 523 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-09more like thismore than 2023-11-09
star this property answer text <p>We have made no such assessment.</p><p>The Major Conditions Strategy will set out how we intend to tackle conditions that contribute most to morbidity and mortality across the population in England which include cancers; cardiovascular disease, including stroke and diabetes; chronic respiratory diseases; dementia; mental ill health; and musculoskeletal conditions.</p> more like this
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-09T17:52:28.317Zmore like thismore than 2023-11-09T17:52:28.317Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4779
star this property label Biography information for Taiwo Owatemi more like this
1667704
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Ferric Maltol: Chipping Barnet more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that Ferric Maltol is available on prescription to people in Chipping Barnet constituency. more like this
star this property tabling member constituency Chipping Barnet more like this
star this property tabling member printed
Theresa Villiers more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 104 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-09more like thismore than 2023-11-09
star this property answer text <p>Clinicians can prescribe any product on the National Health Service they consider necessary for the treatment of their patient unless it is listed in Schedules 1 or 2 to the NHS (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004. Ferric Maltol is not listed in Schedules 1 or 2; however, NHS guidance is that vitamins and minerals should not be routinely prescribed except for when a patient has a medically diagnosed deficiency. This includes those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Ferric Maltol, which may be used to treat iron deficiency, may therefore be prescribed to patients, including those in Chipping Barnet constituency, on that basis.</p><p>It is for the general practitioner or other responsible clinician to work with their patient and decide on the course of treatment, with the provision of the most clinically appropriate care for the individual always being the primary consideration. Clinicians are responsible for making prescribing decisions for their patients, considering best prescribing practice and the local commissioning decisions of their respective integrated care board.</p>
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-09T17:57:40.127Zmore like thismore than 2023-11-09T17:57:40.127Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
1500
star this property label Biography information for Theresa Villiers more like this
1667958
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cystic Fibrosis: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether it is his Department's policy that people with cystic fibrosis will have access to (a) Orkambi, (b) Symkevi and (c) Kaftrio through the NHS. more like this
star this property tabling member constituency Hornsey and Wood Green more like this
star this property tabling member printed
Catherine West more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 346 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-09more like thismore than 2023-11-09
star this property answer text <p>Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.</p><p>NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.</p> more like this
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-09T17:59:10.793Zmore like thismore than 2023-11-09T17:59:10.793Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4523
star this property label Biography information for Catherine West more like this
1668018
star this property registered interest false more like this
star this property date less than 2023-11-07more like thismore than 2023-11-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Abiraterone more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will review the decision to reject the use of the drug Abiraterone to tackle prostate cancer. more like this
star this property tabling member constituency Richmond Park more like this
star this property tabling member printed
Sarah Olney more like this
unstar this property type
WrittenParliamentaryQuestion
star this property uin 377 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2023-11-09more like thismore than 2023-11-09
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that guides the National Health Service on funding new medicines, based on clinical and cost-effectiveness.. The NHS is legally required to fund medicines recommended by NICE, usually within 3 months of final guidance.</p><p>NICE has recommended abiraterone for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone in line with NICE’s recommendations, ensuring access for eligible patients.</p><p>Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is currently considering a clinical policy proposal for abiraterone as a treatment option for potential use in specific cases. The proposal is due to be discussed later this month, with potential stakeholder testing by January 2024, if supported.</p>
star this property answering member constituency Colchester more like this
star this property answering member printed Will Quince more like this
star this property question first answered
less than 2023-11-09T11:00:41.877Zmore like thismore than 2023-11-09T11:00:41.877Z
star this property answering member
4423
star this property label Biography information for Will Quince more like this
star this property tabling member
4591
star this property label Biography information for Sarah Olney more like this